AVTR Q2 Deep Dive: Margin Pressures Mount as Competitive Intensity Rises and Leadership Transition Looms

Life sciences company Avantor (NYSE:AVTR) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.1% year on year to $1.68 billion. Its non-GAAP profit of $0.24 per share was in line with analysts’ consensus estimates.

Is now the time to buy AVTR? Find out in our full research report (it’s free).

StockStory’s Take

Avantor’s second quarter results were met with a sharply negative market reaction, as investors focused on ongoing margin contraction and heightened competitive intensity. Management attributed the quarter’s performance to a combination of pricing actions in the Laboratory Solutions business aimed at protecting and growing market share, as well as discrete operational headwinds in Bioscience Production, including extended maintenance at a manufacturing facility and unexpected challenges at several large bioprocessing customers. CEO Michael Stubblefield acknowledged that, despite sequential improvement in organic revenue, “competitive intensity remains high across our industry,” and noted that these dynamics, along with unfavorable product mix and higher supply chain expenses, weighed on profitability.

Looking ahead, Avantor’s guidance is shaped by ongoing pricing pressure, continued headwinds in key customer segments, and a leadership transition as Emmanuel Ligner prepares to take over as CEO. Management anticipates that margin rates will remain pressured through the rest of the year, especially as new contract wins in Laboratory Solutions come with significant up-front rebates and lower initial profitability. CFO Brent Jones emphasized that while recent share gains are expected to provide future volume tailwinds, “the competitive actions to drive share have come at the cost of margin.” The company remains focused on executing cost transformation measures and leveraging digital and pricing initiatives to drive long-term margin recovery.

Key Insights from Management’s Remarks

Management pointed to a mix of operational setbacks and aggressive commercial strategies as primary factors behind Q2 performance, highlighting the impact of ongoing cost transformation efforts and the need to offset margin pressures.

• Leadership transition announced: Avantor named Emmanuel Ligner as the incoming CEO effective August, bringing over 30 years of life sciences experience—a move expected to inject fresh strategic perspective, particularly in bioprocessing.
• Contract wins drive share gains: The Laboratory Solutions segment secured contract extensions and new awards with major pharmaceutical and biotech customers, including a five-year extension with BIO Business Solutions, resulting in over $100 million in anticipated incremental revenue. These wins reflect successful customer engagement and are expected to bolster future volumes.
• Margin erosion from pricing strategy: To defend and grow market share, the company adopted aggressive pricing tactics, particularly with large biopharma accounts. While this led to material account wins, it also resulted in reduced gross and operating margins, as management prioritized share over near-term profitability.
• Operational and customer-specific headwinds: Bioscience Production faced setbacks due to extended planned maintenance at a key manufacturing site and unexpected order reductions from a handful of large customers in emerging modalities (such as gene therapy and mRNA platforms). These events disrupted the anticipated recovery in bioprocessing.
• Digital platform and process enhancements: Investments in digital capabilities, including the rollout of the Avantor Navigator AI tool and a new pricing optimization platform, were highlighted as key initiatives. Management expects these efforts to improve the customer experience, increase conversion rates, and drive operating efficiency over time.

Drivers of Future Performance

Avantor’s outlook remains cautious, with recovery hinging on volume realization from recent contract wins, stabilization in bioprocessing, and the company’s ability to manage ongoing pricing and margin pressures.

• Realization of contract-driven volume: Recent share gains in Laboratory Solutions are expected to flow through as incremental revenue in coming quarters, but the associated upfront rebates and competitive pricing will continue to weigh on margins until higher volumes drive better absorption and operating leverage.
• Bioprocessing recovery and risk: The pace of recovery in Bioscience Production depends on resolving operational backlogs and overcoming persistent customer-specific demand headwinds. Management flagged continued uncertainty, especially as challenges with key accounts in gene therapy and mRNA are expected to linger through year-end.
• Cost transformation and digital initiatives: The multiyear $400 million cost transformation program remains on track, with management betting on efficiency gains, supply chain improvements, and digital enhancements (like AI-powered solutions) to offset inflationary and competitive pressures. However, the timing and scale of margin recovery remain uncertain.

Catalysts in Upcoming Quarters

In the next few quarters, the StockStory team will closely monitor (1) the pace at which new contract wins in Laboratory Solutions translate into higher volumes and improved operating leverage, (2) signs of stabilization or improvement in the bioprocessing segment as customer-specific headwinds are addressed, and (3) the initial impact of Emmanuel Ligner’s leadership on strategic direction. Progress on cost transformation and digital initiatives will also be key signposts for margin recovery.

Avantor currently trades at $12.70, down from $13.45 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.